Sign up for our Oncology Central weekly news round-up

AACR19 day 1 update: ipilimumab, CAR-T cell therapy and more

Written by Jade Parker, Senior Editor
Cancer biology and pathology Emerging technologies For clinicians For researchers Industry and business News

Today at our booth

Today marked the first day of AACR 2019 in Atlanta. The conference has already been packed with new advancements and data from studies that could significantly impact clinical practice within oncology, such as key data from the TATTON and DART trials. Take a look at some of our highlights below, and tell us your thoughts in the comments.

Remember you can find us at booth #4438, or follow our Twitter updates @OncologyCentral.

Video highlights

Picture of the Day

Visit us at booth 4438 to claim your free tote bag

Tomorrow’s key talk to attend

The DARC side of breast cancer disparities: Links to African ancestry and immunologic tumor responses

(Plenary session two: April 1, 8:15 AM–10:15 AM Hall A – Convention Center)

Today’s news

MET inhibitor savolitinib shows promise for EGFR-mutant NSCLC

The addition of the investigational MET inhibitor savolitinib to the EGFR inhibitor osimerinib (Tagrisso®) is beneficial for certain pre-treated patients with EGFR-mutant non-small cell lung cancer (NSCLC), according to results from the TATTON trial.

Find out further details.

Ipilimumab, nivolumab combination demonstrates efficacy in high-grade neuroendocrine carcinoma

Results from the DART Phase II clinical trial indicate that a therapeutic combination of the anti-CTLA-4 immunotherapeutic, ipilimumab (Yervoy®), and the anti-PD-1 immunotherapeutic, nivolumab (Opdivo®), may be beneficial to patients with rare, high-grade neuroendocrine carcinoma.

Read the full story.

Mesothelin targeted CAR-T cell therapy – a possible treatment for solid tumors

A novel CAR-T cell therapy that targets the mesothelin protein has shown no toxicity and antitumor activity in patients with malignant pleural disease from mesothelioma.

Discover further details.

HER2 targeted CAR-T cell therapy shows promise in advanced sarcomas patients

A combination therapy that uses both chemotherapy and CAR-T cells engineered to target the HER2 protein has been found to be safe and showed clinical response in paediatric and adult patients that have advanced HER2+ sarcoma.

Find out more.

Excess body weight before age 50 is associated with higher pancreatic cancer mortality risk

Excess weight before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess weight at older ages, according to a new study.

Read the fully story.

Best of social media #AACR19